Breast cancer begins when cells in the breast grow out of control, forming a tumor that can damage surrounding tissue and, if untreated, spread to distant organs. What it does to your body depends on how far it has progressed, but the process follows a pattern: local growth, regional spread to nearby lymph nodes, and eventually metastasis to bones, lungs, liver, or brain. Understanding each stage of that process helps make sense of the symptoms, the stakes, and why early detection changes outcomes so dramatically.
How It Starts in the Breast
Most breast cancers begin in the milk ducts or the small glands (lobules) that produce milk. In the earliest form, called ductal carcinoma in situ, abnormal cells are confined to the lining of a duct and haven’t broken through into surrounding tissue. At this point the cancer can’t spread, and it’s highly treatable.
When those cells do break through the duct wall, the cancer becomes invasive. Invasive ductal carcinoma is the most common type. Once tumor cells reach the surrounding breast tissue, they begin recruiting blood vessels to fuel their growth and can start interacting with nearby nerves. Research from the National Cancer Institute has shown that blood vessels within tumors release molecules that draw sensory nerves closer. Those nerves then release a small protein that, paradoxically, kills a subset of cancer cells. But when those cells die, they release genetic material that flips a switch in the surviving cancer cells, activating genes that drive further growth and spread. In other words, even cell death within a tumor can accelerate the disease.
What Drives Different Types
Not all breast cancers behave the same way. Their behavior depends largely on which receptors sit on the surface of the tumor cells. About 70% of breast cancers are fueled by hormones: estrogen, progesterone, or both. These cancers have receptors that grab onto those hormones the way a lock accepts a key, and the hormones tell the cells to keep dividing. This is why treatments that block hormone signaling can be effective against these tumors.
Roughly 20% to 25% of breast cancers overexpress a protein called HER2, which acts as a powerful growth signal on its own. HER2-positive cancers tend to grow more aggressively. Complicating matters, cancer cells can adapt when treatment targets one growth pathway. When HER2 signaling is blocked by therapy, some tumors respond by switching on their estrogen receptors instead. In clinical studies, 18% of tumors that were originally estrogen-receptor-negative converted to estrogen-receptor-positive after anti-HER2 treatment, essentially finding a backup fuel source.
A smaller percentage of breast cancers lack all three common receptors (estrogen, progesterone, and HER2). These “triple-negative” cancers have fewer targeted treatment options and often grow faster.
Physical Changes You Can See and Feel
The physical signs of breast cancer vary, and some people have no symptoms at all in the early stages. According to the CDC, warning signs include:
- A new lump in the breast or underarm area
- Thickening or swelling of part of the breast
- Dimpling or irritation of the skin
- Redness or flaky skin on the nipple or breast
- Nipple pulling inward or nipple pain
- Discharge from the nipple other than breast milk, including blood
- Any change in the size or shape of the breast
- Pain in any area of the breast
One aggressive form, inflammatory breast cancer, mimics a breast infection so closely that it’s often initially misdiagnosed. Instead of a distinct lump, the breast becomes red, swollen, and warm, with a dimpled texture that looks like orange peel. These symptoms cover more than a third of the breast and develop within three months. Compared to a typical breast infection (mastitis), inflammatory breast cancer tends to involve swelling more often and take longer to fully appear, averaging about 38 days versus 13 days for mastitis. If antibiotics don’t resolve what looks like an infection, further testing is critical.
How It Spreads Beyond the Breast
Breast cancer spreads through two main routes: the lymphatic system and the bloodstream. The lymph nodes under your arm (axillary nodes) and near your collarbone are typically the first stops. Doctors evaluate spread using a staging system based on tumor size, lymph node involvement, and whether the cancer has reached distant organs.
Tumor size alone tells part of the story. A tumor 20 mm or smaller is classified as T1, while one larger than 50 mm is T3. A tumor that has grown into the chest wall or skin is T4. Lymph node involvement ranges from none (N0) to cancer found in 10 or more nodes or in nodes above the collarbone (N3). When cancer reaches distant organs, the staging classification shifts to M1, which corresponds to stage IV disease.
From the lymph nodes, the four most common destinations for metastatic breast cancer are the bones, lungs, liver, and brain. Each site creates its own set of problems. Bone metastases can cause deep, persistent pain and weaken bones enough to cause fractures. Lung metastases may lead to shortness of breath or a chronic cough. Liver involvement can cause abdominal swelling, jaundice, and nausea. Brain metastases can trigger headaches, vision changes, seizures, or personality shifts.
What It Does to the Whole Body
Even before cancer visibly spreads, it can affect how your entire body feels. People with breast cancer frequently experience pain, persistent fatigue, and nausea. These aren’t just side effects of treatment. The tumor itself triggers systemic inflammation, which is linked to reduced physical function and a measurable decline in overall well-being. Fatigue from cancer is different from ordinary tiredness: it doesn’t improve much with rest and can persist for months or longer.
Advanced breast cancer can also disrupt your body’s chemistry. Bone metastases sometimes release excess calcium into the bloodstream, a condition called hypercalcemia, which causes confusion, excessive thirst, nausea, and in severe cases, heart rhythm problems. Weight loss and muscle wasting (cachexia) can develop as the cancer competes with healthy tissue for the body’s energy and nutrients. These systemic effects are often what make advanced cancer feel like a whole-body illness rather than a problem in one location.
Breast Cancer in Men
About 1 in every 100 breast cancers diagnosed in the United States occurs in a man. Men have a small amount of breast tissue, and cancer develops there the same way it does in women, most often as invasive ductal carcinoma. The symptoms are similar: a lump or swelling, skin dimpling, nipple discharge, or nipple retraction.
Risk factors for men include getting older (most cases are diagnosed after age 50), carrying BRCA1 or BRCA2 gene mutations, having a family history of breast cancer, and conditions that raise estrogen levels relative to androgens. Klinefelter syndrome, liver cirrhosis, and obesity all shift that hormonal balance. Prior radiation therapy to the chest also increases risk. Because breast cancer in men is rare and often not on anyone’s radar, it tends to be diagnosed at a later stage, when the tumor is larger or has already spread to lymph nodes.
How Staging Shapes the Outlook
What breast cancer ultimately does to your body depends enormously on when it’s caught. At stage 0, abnormal cells are contained within a duct and the five-year survival rate is close to 100%. At stage I, the tumor is small and confined to the breast. By stage III, cancer has spread extensively to regional lymph nodes but not to distant organs. Stage IV means the cancer has metastasized to bones, lungs, liver, brain, or other distant sites.
Each jump in stage reflects a cancer that has gained more ability to invade tissue, recruit blood supply, evade the immune system, and establish itself in new organs. The biological process is not a single event but a cascade: tumor cells remodel their local environment, enter blood or lymph vessels, survive the journey, and colonize a new organ. That’s why treatments often combine strategies targeting the tumor itself, its hormone or growth receptors, and the immune system’s ability to recognize cancer cells. The earlier that cascade is interrupted, the more effective those treatments tend to be.